Anterior Uveitis (Iritis)
Clinical Snapshot
Anterior uveitis (also called iritis, or iridocyclitis when the ciliary body is also clearly involved) is inflammation of the anterior uveal tract — the iris and/or ciliary body, the pigmented, vascular middle layer of the eye that also includes the choroid posteriorly. It is one of four anatomic categories in the Standardization of Uveitis Nomenclature (SUN) Working Group classification — anterior, intermediate, posterior, and panuveitis, defined by the primary site of inflammation within the eye — and anterior uveitis is by far the most common, accounting for roughly half of all uveitis presentations.[1][2]
This chapter exists because anterior uveitis is a genuine ophthalmic emergency that can look, at a glance, like a much more ordinary complaint. A patient describing "a red, irritated eye" puts the pharmacist or primary care provider in front of the single most consequential decision in that encounter: distinguishing this condition from benign, self-limited causes of red eye such as viral, bacterial, or allergic conjunctivitis. Recommending an over-the-counter antihistamine/decongestant drop or an antibiotic drop for what is actually anterior uveitis does not just fail to help — it delays vision-threatening treatment while inflammation continues to damage the eye. The differential diagnosis in Recognize the Condition is, deliberately, the single most important content in this chapter.
Population-based data (from a large United States managed-care cohort) place the overall incidence of uveitis at approximately 25 cases per 100,000 person-years, with a point prevalence around 58 per 100,000 — women affected somewhat more often than men in prevalence, though incidence is roughly equal between the sexes.[2] No single cause explains most cases: idiopathic anterior uveitis — inflammation with no identifiable systemic, infectious, or traumatic cause found on a reasonable workup — is the single largest category, accounting for roughly half to two-thirds of presentations in most series, ahead of every specific identifiable cause individually.[2] The remainder spans autoimmune/systemic-disease associations (most classically the HLA-B27-associated spondyloarthropathies), infectious causes, trauma, and — occasionally — a medication; see Etiology and Risk Factors for the full breakdown.
Whatever the cause, the shared final pathway is inflammation within the anterior chamber — the fluid-filled space between the cornea and the iris/lens — with inflammatory cells and protein (flare) accumulating in the aqueous humor. This is what a slit-lamp examination is specifically designed to detect, and it is the definitive finding that separates a confirmed diagnosis of anterior uveitis from every one of its look-alikes (see Assessment and Diagnosis). Because that examination requires equipment not available in a typical community pharmacy or primary-care office, this chapter's central message is recognition and prompt referral, not pharmacist-level diagnosis or management.
Recognize the Condition
Symptoms
The symptom pattern of anterior uveitis is what should first raise suspicion, well before any examination finding is available. Classic anterior uveitis presents with a triad of photophobia, eye pain, and blurred vision, often accompanied by redness and, less consistently, tearing.[2][3] Each of these features tends to be more prominent, and qualitatively different, than what patients describe with ordinary conjunctivitis:
- Photophobia is frequently severe — patients may specifically avoid light, want the lights off, or wear sunglasses indoors — because inflamed uveal tissue makes ciliary muscle contraction and pupillary constriction to light both painful. This is uncommon in conjunctivitis, and when present at all is typically mild.
- Pain is deep and aching, felt within or behind the eye rather than on its surface, and often worsens with attempts to focus at near (from ciliary spasm) or with direct light exposure. This contrasts with the mild surface irritation, grittiness, or foreign-body sensation typical of conjunctivitis.
- Vision can be measurably reduced, from a combination of anterior chamber inflammation, corneal edema, and iris/pupil involvement — conjunctivitis, by contrast, typically preserves visual acuity (any blur usually clears with a blink, as discharge is wiped away).
The critical distinction: anterior uveitis versus conjunctivitis
Because both conditions can present as "a red eye," and because the wrong initial recommendation genuinely delays sight-saving treatment, a systematic side-by-side comparison is the most useful tool a pharmacist or primary care provider has at the point of first contact.
| Feature | Anterior uveitis (iritis) | Conjunctivitis (viral / bacterial / allergic) |
|---|---|---|
| Photophobia | Prominent, often severe | Absent or mild |
| Pain | Deep, aching, ocular/periocular pain, worse with near focus | Mild irritation, grittiness, foreign-body sensation |
| Pupil | Often small, sluggish, or irregular (ciliary spasm; posterior synechiae) | Normal size and reactivity |
| Visual acuity | Can be reduced | Typically preserved |
| Pattern of redness | Ciliary flush — concentrated in a ring around the limbus | Diffuse conjunctival injection, often more pronounced toward the periphery/fornices |
| Discharge | Absent or minimal (watery at most) | Often present — purulent (bacterial), watery (viral), or stringy/mucoid with itch (allergic) |
| Itching | Not a typical feature | A hallmark of allergic conjunctivitis specifically |
| Anterior chamber | Cells and flare on slit-lamp exam — the definitive finding | Clear |
No single feature is entirely sufficient on its own — mild photophobia can occur with severe conjunctivitis from light sensitivity of an irritated surface, for instance — but the combination of photophobia with genuine pain, any pupil abnormality, or any reduction in vision should be treated as anterior uveitis until an ophthalmologist proves otherwise, not managed as routine conjunctivitis while awaiting reassessment. See Red Flags for Referral.
Other findings
More severe presentations can show a hypopyon — a visible layer of white blood cells settling in the inferior anterior chamber — which is itself a marker of more severe inflammation and warrants urgent same-day assessment regardless of the presumed cause.[2] Keratic precipitates (clumps of inflammatory cells deposited on the back surface of the cornea) and posterior synechiae (adhesions between the iris and the underlying lens, which can distort pupil shape or produce a fixed, irregular pupil) are further slit-lamp findings that confirm the diagnosis and help gauge chronicity and severity, but — like the anterior chamber cell-and-flare finding itself — none of these are assessable without a slit lamp.[2]
Risk Factors
Anterior uveitis has no single cause; it is better understood as a shared inflammatory endpoint reached by several distinct pathways. Categorizing the possibilities is what drives both the initial workup decision (see Assessment and Diagnosis) and, where a cause is identified, coordinated management of the underlying disease.
Idiopathic
No identifiable cause is found in the majority of cases even after a reasonable workup — idiopathic anterior uveitis accounts for roughly half to two-thirds of presentations in most published series, making it the single largest category overall, ahead of any specific identified cause.[2] A first, mild, unilateral episode in an otherwise healthy adult is often managed with topical therapy alone without an exhaustive systemic workup; that workup becomes more clearly indicated when the presentation is severe, bilateral, recurrent, or chronic (see Assessment and Diagnosis).[4]
Autoimmune / systemic disease-associated
A substantial share of the remaining cases occur alongside a systemic autoimmune or inflammatory disease, and identifying one changes both the anticipated disease course and who else needs to be involved in the patient's care.
- HLA-B27-associated spondyloarthropathies are the classic and single most important systemic association. Roughly half of all acute anterior uveitis cases occur in HLA-B27-positive individuals, and the association runs in both directions — about a third of patients with ankylosing spondylitis, and about a quarter of those with psoriatic arthritis, will develop at least one episode of acute anterior uveitis.[5] HLA-B27-associated disease also has a distinctive clinical pattern worth recognizing on its own: episodes are typically unilateral (though they can alternate between eyes over time), non-granulomatous, acute in onset, and prone to recur — about two-thirds of patients experience at least one relapse, and roughly a third go on to have three or more.[5] Ankylosing spondylitis is the prototypical association; reactive arthritis, psoriatic arthritis, and the arthritis associated with inflammatory bowel disease round out the seronegative spondyloarthropathy group most consistently linked to HLA-B27-associated uveitis.
- Inflammatory bowel disease (Crohn disease and ulcerative colitis) is independently associated with anterior uveitis, whether or not an associated spondyloarthropathy is also present.
- Sarcoidosis — a multisystem granulomatous disease — is a well-recognized cause, sometimes with a more granulomatous pattern of inflammation (larger, "mutton-fat" keratic precipitates) than the typical HLA-B27 picture.
- Juvenile idiopathic arthritis (JIA) is the most important cause to recognize in children, with a presentation that differs importantly from the adult pattern described above — it is very often entirely asymptomatic. See Special Populations for the pediatric screening pathway.
- Other systemic associations include Behçet disease and tubulointerstitial nephritis and uveitis (TINU) syndrome.[2]
Infectious
Infectious causes account for a meaningful minority of cases — on the order of one in five in published series — and are disproportionately important to identify because they change treatment entirely: an infection needs to be treated, not just immunosuppressed.[2]
- Herpes simplex virus (HSV) and varicella zoster virus (VZV) are the most common viral causes; herpetic anterior uveitis is classically unilateral, often recurrent, and can present with elevated (rather than normal or low) intraocular pressure and patchy iris atrophy from the virus's direct effect on iris tissue — findings that point specifically toward a herpetic cause rather than the more typical HLA-B27 or idiopathic pattern.
- Syphilis is sometimes called "the great masquerader" for its ability to mimic almost any pattern of intraocular inflammation, and serologic screening for it is considered a reasonable, low-cost addition to the workup essentially whenever any systemic workup is being done at all.[2]
- Tuberculosis is an important infectious cause to consider, particularly with relevant exposure history, and is screened for with chest imaging and interferon-gamma release assay or tuberculin skin testing when the workup is undertaken.[2][4]
Traumatic
Blunt or penetrating ocular trauma, and intraocular surgery, can each precipitate anterior chamber inflammation — traumatic iritis. A clear history of recent trauma or surgery is usually apparent, but any post-traumatic red, painful eye still warrants prompt ophthalmology assessment rather than reassurance, since trauma can also cause other sight-threatening injury that a slit-lamp and dilated exam are needed to rule out.
Drug-induced
A number of systemic medications are recognized, uncommon causes of anterior uveitis — worth specifically asking about when a patient reports new eye symptoms after starting a new medication, and worth flagging for the prescriber rather than assuming the eye finding is unrelated.[2]
- Bisphosphonates (used for osteoporosis and other bone conditions) are a recognized, if uncommon, cause — reported after both intravenous agents (e.g., zoledronic acid, pamidronate) and oral agents (e.g., alendronate, risedronate). Onset can be rapid, within hours to a few days of exposure, particularly with intravenous administration, and inflammation generally improves once the bisphosphonate is stopped and any needed topical anti-inflammatory therapy is given.
- Rifabutin, used for Mycobacterium avium complex prophylaxis and treatment (most often in HIV-positive patients), is a well-documented cause, particularly at higher doses or when combined with other drugs that inhibit its metabolism — a reminder to check for interacting medications whenever rifabutin-associated uveitis is suspected.
- Sulfonamide antibiotics are a rarer cause, occasionally in the context of a broader hypersensitivity reaction.
In every drug-induced case, management centers on identifying and, in discussion with the prescriber, discontinuing or substituting the likely culprit alongside whatever topical therapy the treating ophthalmologist prescribes for the inflammation itself — see Non-Pharmacologic Management and Common Errors to Avoid.
Red Flags & Refer
This entire chapter can be summarized as a single message: photophobia with eye pain, plus any pupil abnormality or reduced vision, is a genuine ophthalmic emergency. It requires same-day ophthalmology evaluation — not routine optometry follow-up, not "try an artificial tear and see how it looks in a few days," and not an over-the-counter antihistamine, decongestant, or antibiotic drop.
Untreated or delayed-treatment anterior uveitis is not a benign, self-resolving problem. Persistent anterior chamber inflammation drives a set of complications that are each, independently, a cause of permanent vision loss:
- Posterior synechiae — adhesions between the iris and the lens — can distort the pupil, obstruct aqueous outflow, and (if extensive, forming seclusio pupillae) precipitate acute secondary angle-closure glaucoma.
- Secondary glaucoma can result from synechiae obstructing outflow, from inflammatory debris clogging the trabecular meshwork, or — once treatment starts — from a steroid response to the very corticosteroids used to treat the inflammation (see Monitoring and Follow-Up).
- Cataract can develop both from chronic inflammation itself and from prolonged corticosteroid exposure.
- Cystoid macular edema — fluid accumulation in the central retina — is a recognized cause of reduced central vision, even when the anterior chamber inflammation itself is eventually controlled.
- Band keratopathy (calcium deposition across the corneal surface) can develop with chronic disease.
Cohort data attribute roughly 10% of legal blindness in the United States to uveitis and its complications — a reminder that this is a genuinely sight-threatening disease category, not a cosmetic red eye.[2]
Additional findings that should prompt urgent (same-day) referral, beyond the core photophobia-pain-pupil-vision pattern:
- A visible hypopyon (layered white cells in the anterior chamber).
- Any red, painful eye in a contact lens wearer — stop lens wear immediately and refer urgently; this needs to be distinguished from microbial keratitis, which is a separate sight-threatening emergency with an overlapping presentation.
- Recurrent episodes, bilateral disease, or an atypical first presentation — these change the workup (see Assessment and Diagnosis) and should not simply be treated the same way as a routine first episode.
- Any red or painful eye in a child — pediatric anterior uveitis, especially JIA-associated disease, is often silent rather than painful and red, so any ocular finding in a child with known or suspected JIA warrants prompt ophthalmology input rather than a "watch and wait" approach; see Special Populations.
- New eye symptoms after starting a medication associated with drug-induced uveitis (see Etiology and Risk Factors) — flag for both the prescriber and an ophthalmology assessment.
- Worsening despite treatment, a new or rising intraocular pressure, or any new visual field or acuity change during a course of therapy already underway.
The default posture with a suspected case is to refer, not to trial a self-care recommendation and reassess — unlike most other chapters in this platform, this one is deliberately not built around a pharmacist-managed stepwise treatment ladder, because there isn't one. See Choose Initial Treatment.
Assessment & Diagnosis
The definitive diagnosis requires a slit lamp
Anterior uveitis is diagnosed by slit-lamp biomicroscopy, which allows direct visualization of cells (individual white blood cells suspended in the aqueous humor) and flare (a hazy, "foggy" appearance caused by increased protein concentration in the aqueous, from breakdown of the blood-aqueous barrier) within the anterior chamber. The Standardization of Uveitis Nomenclature (SUN) Working Group's consensus grading scheme scores both cells and flare on a standardized 0 to 4+ scale, giving ophthalmologists a reproducible way to document severity and track response to treatment over time.[1]
This examination — and therefore the actual, confirmed diagnosis — is not something a community pharmacy or a typical primary-care office is equipped to perform. This is precisely why this chapter's message is recognition of the clinical pattern (Recognize the Condition) and prompt referral (Red Flags for Referral), rather than a pharmacist-level diagnostic pathway. A patient who "looks like" they might have uveitis, based on the symptom-and-sign pattern above, should be referred for the slit-lamp examination that can actually confirm or rule it out — not observed further while the diagnosis remains presumptive.
When a systemic workup is warranted
Not every patient with a first episode of anterior uveitis needs an extensive systemic workup — a mild, unilateral, typical-appearing first episode in an otherwise well adult is often treated empirically with topical therapy while it is monitored for response. A systemic workup becomes more clearly appropriate for uveitis that is severe, bilateral, recurrent, or chronic, or that has atypical features (granulomatous keratic precipitates, an unusual age at onset, or associated systemic symptoms).[4] A reasonable, commonly used initial panel in that setting includes:[4][2]
- HLA-B27 typing — given how strong and common the association is with acute anterior uveitis.
- Syphilis serology (e.g., a treponemal test with reflex non-treponemal confirmation) — syphilis can mimic almost any uveitis pattern.
- Serum angiotensin-converting enzyme (ACE) and chest imaging — screening for sarcoidosis.
- Tuberculosis screening (interferon-gamma release assay or tuberculin skin test) — particularly with relevant exposure history.
Additional targeted testing (for example, inflammatory bowel disease workup, rheumatologic serologies, or specific infectious testing) is guided by the individual patient's history and examination findings rather than ordered reflexively in every case — this workup, like the diagnosis itself, is directed by the treating ophthalmologist, in many cases in coordination with rheumatology, infectious disease, or the patient's existing specialist for a known systemic condition.
Treatment Targets
- Control anterior chamber inflammation promptly, to relieve symptoms and limit the duration of active disease.
- Prevent vision-threatening complications — posterior synechiae, secondary glaucoma, cataract, cystoid macular edema, and band keratopathy — rather than treating only to symptomatic comfort.
- Identify, and coordinate treatment of, any underlying systemic or infectious cause, rather than treating the eye in isolation when a systemic association is present.
- Use corticosteroid therapy at the lowest effective intensity and duration needed to control inflammation, balanced against its own risk of raising intraocular pressure and accelerating cataract.
- Recognize recurrent or chronic disease early enough to escalate to systemic, steroid-sparing therapy before repeated corticosteroid courses themselves become the dominant source of ocular morbidity.
- At the pharmacist and primary-care level specifically: recognize the clinical pattern promptly and refer without delay — this condition's outcomes are determined far more by how quickly it reaches an ophthalmologist than by anything manageable outside that setting.
Choose Initial Treatment
Every element of anterior uveitis pharmacotherapy is ophthalmology-specialist-initiated
Unlike most conditions in this platform's Clinical Guidelines library, there is no pharmacist-initiated or primary-care-initiated treatment ladder here. Topical corticosteroids, cycloplegics, and any systemic immunosuppressive therapy are all selected, dosed, and monitored by the treating ophthalmologist (and, for systemic therapy, typically co-managed with rheumatology or the relevant disease specialist). The pharmacist's role is recognition, referral, and — once a regimen has been started — reinforcing adherence and flagging concerns back to the prescriber, not initiating or substituting therapy.[4][2]
Topical corticosteroids — first-line for controlling inflammation
A topical corticosteroid drop is the mainstay of initial treatment for confirmed anterior uveitis, typically started at a relatively high frequency in more significant inflammation and then tapered gradually over weeks as the anterior chamber reaction resolves.[2] Never discontinued abruptly once a taper has begun — stopping suddenly risks a rebound flare of inflammation, and the taper schedule set by the ophthalmologist should be followed exactly, with the patient counselled not to stop early simply because the eye "feels better." Every course of topical corticosteroid therapy needs a defined follow-up plan to monitor intraocular pressure, since steroid-induced ocular hypertension and glaucoma are a genuine risk with this drug class, particularly with more potent agents or longer courses (see Monitoring and Follow-Up).
Cycloplegic / mydriatic agents — relieving spasm, protecting the pupil
A cycloplegic drop — cyclopentolate or atropine — is used alongside the corticosteroid for two distinct reasons: it paralyzes the ciliary muscle, relieving the deep, aching pain from ciliary spasm that is such a prominent symptom of anterior uveitis, and it dilates the pupil, which helps prevent (and can help break) posterior synechiae — the adhesions between the iris and the lens that form when an inflamed, still-mobile iris comes into prolonged contact with the lens surface.[2] Cyclopentolate is shorter-acting and more often used for milder disease; atropine's longer duration of action makes it useful for more severe pain or when actively working to break early synechiae, at the cost of a longer period of blurred near vision and photophobia after each dose. Counsel patients that this blurred near vision and light sensitivity is an expected, reversible effect of the cycloplegic itself — not a sign the treatment isn't working or that the disease is worsening.
Systemic immunosuppressive therapy — for recurrent or systemic-disease-associated cases
Most anatomically isolated episodes of anterior uveitis resolve with topical therapy alone. Escalation to systemic immunomodulatory therapy is considered specifically when a patient responds poorly to corticosteroids, develops corticosteroid-limiting side effects, needs an unacceptably high maintenance dose of topical steroid to keep inflammation controlled, or has a concomitant systemic inflammatory disease that itself warrants systemic treatment.[4] Conventional steroid-sparing agents (methotrexate, azathioprine, mycophenolate mofetil, oral cyclosporine) and biologic agents (adalimumab — Health Canada-approved specifically for non-infectious uveitis in appropriate patients — and infliximab) are the agents most often used, selected and monitored by the uveitis specialist or rheumatology, generally in coordination with any underlying systemic disease the patient already carries a diagnosis for.[4][2]
Treating an identified underlying cause
Where a specific cause is found, treatment addresses it directly rather than relying on anti-inflammatory therapy alone: an oral antiviral (acyclovir or valacyclovir) for herpes simplex- or varicella zoster-associated disease, alongside topical therapy for the inflammation itself; discontinuation of a culprit medication for drug-induced uveitis, done in discussion with the prescriber rather than unilaterally; and referral to the relevant specialist (rheumatology for a spondyloarthropathy or inflammatory bowel disease, infectious disease for tuberculosis or syphilis) for any identified systemic disease.
Non-Pharmacologic Treatment
- Sunglasses or tinted lenses provide genuine symptomatic relief from the severe photophobia of active anterior uveitis, and are also useful during the period of pupil dilation from cycloplegic therapy, when light sensitivity is compounded by the dilated pupil itself.
- Avoid contact lens wear during active inflammation and for the duration of topical corticosteroid therapy — both the inflamed ocular surface and the corticosteroid drop itself increase infection risk with continued lens wear.
- Do not recommend over-the-counter redness relievers, antihistamine/decongestant drops, or antibiotic drops for a presentation consistent with anterior uveitis. None of these treat the underlying anterior chamber inflammation, a vasoconstrictor can mask the ciliary flush pattern that is itself a useful diagnostic clue, and the delay while "trying" one of these products is exactly the delay that risks the complications in Red Flags for Referral.
- Reinforce adherence to the taper schedule once an ophthalmologist has started topical corticosteroid therapy — stopping early because symptoms have improved is one of the more common, avoidable reasons for a rebound flare (see Choose Initial Treatment).
- Medication review — where a drug-induced cause is suspected (see Etiology and Risk Factors), flag the suspected medication for discussion with the prescriber rather than recommending the patient stop it unilaterally, particularly for a medication (such as a bisphosphonate) being taken for an important underlying condition.
- Coordinate with the patient's other specialists when a systemic disease is identified or already known — a patient with ankylosing spondylitis, inflammatory bowel disease, sarcoidosis, or JIA benefits from their rheumatologist, gastroenterologist, or other treating specialist being made aware of a new or recurrent uveitis episode, both for coordinated care and because it may prompt a change in their systemic disease management.
- Patient education on recurrence — patients with a first episode, and especially those with an HLA-B27-associated pattern, benefit from knowing what a recurrence would feel like (the same photophobia-pain-redness pattern, possibly in the other eye) and that a recurrence should prompt the same urgent response as a first episode, not a "wait and see" approach because "I've had this before and it went away."
Special Populations
Pediatrics — juvenile idiopathic arthritis (JIA)
Pediatric anterior uveitis differs from the adult presentation in a way that matters enormously for how it is caught: JIA-associated chronic anterior uveitis is very often entirely asymptomatic — a quiet, white, pain-free eye that nonetheless has significant anterior chamber inflammation on slit-lamp exam. This is precisely why children with JIA are managed with a scheduled, risk-stratified screening program rather than being examined only when a red or painful eye prompts a visit.[6]
Chronic anterior uveitis develops in up to 20% of children with JIA, and Canadian Rheumatology Association guidance (endorsed by the Canadian Ophthalmological Society Board) puts the cumulative incidence of new-onset uveitis at 13.9% within the first 5 years after a JIA diagnosis.[6] The strongest risk factors are female sex, young age at JIA onset (under 7 years), and antinuclear antibody (ANA) positivity — patients with this combination of risk factors are screened most intensively.[6] The guideline recommends an initial ophthalmologic examination within 1 to 3 months of JIA diagnosis for higher-risk patients, followed by ongoing screening at least every 3 months for the first 4 years.[6] A concrete treatment-escalation threshold from the same guideline: systemic (steroid-sparing) therapy is recommended once topical corticosteroid use exceeds more than 2 drops per day of prednisolone acetate 1% for at least 3 months — a useful marker, even outside pediatrics, of when topical therapy alone has stopped being an adequate long-term plan.[6]
The practical takeaway for a pharmacist or primary-care provider: do not use the absence of a red, painful eye to reassure a family that a child with JIA does not have uveitis, and do not treat a missed screening visit as low-stakes — this is a scheduled screening program specifically because the disease it is designed to catch has no symptoms to prompt a visit on its own.
Pregnancy and breastfeeding
Topical ocular therapies (corticosteroid drops, cycloplegics) have minimal systemic absorption, and topical corticosteroid therapy for a genuinely vision-threatening indication is generally continued through pregnancy under ophthalmology direction rather than withheld. Systemic immunosuppressive therapy is a different matter — methotrexate and mycophenolate mofetil are teratogenic and contraindicated in pregnancy, and any patient on these agents who is pregnant or planning pregnancy needs a coordinated plan with the prescribing specialist well in advance. Biologic agents and other steroid-sparing options are individualized in pregnancy by the treating specialist rather than by default substitution.
Contact lens wearers
A red, painful eye in a contact lens wearer needs to be distinguished from microbial keratitis, a separate sight-threatening emergency with an overlapping presentation (pain, photophobia, redness) — both need the lens removed immediately and urgent same-day assessment, and neither should be managed by simply recommending a lubricant and reassessing in a few days. See Red Flags for Referral.
HLA-B27-positive patients
Patients with known HLA-B27-associated disease (or a first episode found on workup to be HLA-B27-associated) benefit from being told explicitly that recurrence is common — roughly two-thirds have at least one further episode, sometimes in the other eye — so that a future episode is recognized and acted on promptly rather than dismissed as "the same old thing that always goes away."[5]
Immunocompromised patients
In immunocompromised patients — most notably those with HIV — infectious causes (cytomegalovirus, syphilis, tuberculosis) are disproportionately more likely, and rifabutin used for Mycobacterium avium complex prophylaxis is itself a recognized cause of drug-induced uveitis in this population (see Etiology and Risk Factors) — worth specifically considering when a patient on rifabutin develops new eye symptoms.
Older adults
Older adults often carry a higher baseline risk of glaucoma and cataract independent of uveitis, which makes the intraocular-pressure and lens-clarity monitoring that accompanies any topical corticosteroid course even more important in this group — a steroid response superimposed on existing glaucoma risk is a genuinely higher-stakes scenario than in a younger patient with no baseline ocular comorbidity.
Monitoring & Follow-Up
Anterior uveitis is managed entirely by ophthalmology, but a pharmacist's ongoing role — reinforcing what to watch for, and recognizing when something needs to go back to the prescriber sooner than the next scheduled visit — genuinely matters across the course of treatment.
- Intraocular pressure monitoring is a required part of any topical corticosteroid course, at a schedule set by the treating ophthalmologist — this is not optional or something to defer because symptoms have improved, since steroid-induced ocular hypertension can develop silently.
- Taper adherence — the corticosteroid dose is reduced on a defined schedule as inflammation resolves, confirmed at follow-up visits by repeat slit-lamp grading of cells and flare rather than by symptoms alone, since the anterior chamber can still show active inflammation after symptoms have largely settled.[1]
- Recurrence vigilance, particularly for HLA-B27-associated and other recurrence-prone patterns — a returning photophobia-pain-redness pattern, in either eye, should prompt the same urgent response as a first episode (see Special Populations).
- Scheduled screening adherence for children with JIA — attendance at every screening visit matters specifically because the disease being screened for typically has no symptoms of its own to otherwise prompt a visit (see Special Populations).[6]
- Confirming resolution after a drug-induced cause is addressed — inflammation is expected to improve once the culprit medication is stopped and topical therapy is given; persistence despite this should prompt reconsideration of the diagnosis rather than an assumption that "it just needs more time."
- Systemic therapy monitoring — patients on methotrexate, azathioprine, mycophenolate, or a biologic agent need the standard laboratory and clinical monitoring for those drug classes, coordinated by the prescribing specialist; a pharmacist reviewing a patient's full medication list should confirm this monitoring is actually in place rather than assuming it is being handled elsewhere.
Common Errors to Avoid
- Misdiagnosing anterior uveitis as conjunctivitis and recommending an over-the-counter antihistamine/decongestant or antibiotic drop — the single most consequential error this chapter exists to prevent, since it delays vision-threatening treatment.
- Recommending a vasoconstrictor "redness reliever" for a red eye with a ciliary flush pattern — it can mask the very finding that should be prompting urgent referral.
- Treating photophobia and eye pain as "probably just dry eye" or "probably just conjunctivitis" without checking pupil appearance and visual acuity, or asking specifically about the character of the pain.
- Adopting a "try something and reassess in a few days" approach for a presentation consistent with anterior uveitis — appropriate for routine conjunctivitis, but not for a condition where delay itself causes permanent complications.
- Assuming a normal-looking eye on casual inspection, without a slit lamp, rules out anterior uveitis — cells and flare, the defining finding, are not visible without one.
- Assuming a child's eyes are fine because they are not red or painful — JIA-associated uveitis is frequently asymptomatic, which is exactly why scheduled screening (not symptom-triggered visits) is the recommended pathway.
- Treating a recurrent episode as lower-stakes than a first episode ("it's just the usual thing, it'll go away") rather than with the same urgency.
- Not asking about new medications — particularly bisphosphonates or rifabutin — when a patient reports new eye redness, pain, or photophobia.
- Advising or supporting abrupt discontinuation of a topical corticosteroid taper once ophthalmology has started one, because symptoms have improved.
- Treating a red, painful eye in a contact lens wearer as routine irritation rather than an urgent rule-out for both uveitis and microbial keratitis.
- Recommending a patient stop a systemic medication (such as a bisphosphonate) unilaterally because it appears on the drug-induced uveitis list, without involving the prescriber.
- Missing bilateral, recurrent, or atypical disease as a trigger for a systemic workup and simply re-treating each episode topically in isolation.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Topical Corticosteroids (Ophthalmology-Initiated)
First-line for anterior chamber inflammation, always ophthalmology-selected and monitored with an explicit taper plan. Every course needs scheduled intraocular pressure and lens-clarity follow-up.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisolone acetate 1% ophthalmic suspension | Adults: 1 drop every 1-2 hours while awake initially in more significant inflammation, then tapered over weeks per ophthalmology-directed schedule | Elevated intraocular pressure/steroid-induced glaucoma, cataract with prolonged use, delayed corneal healing | None significant at standard ophthalmic doses | Usual first-choice topical corticosteroid; frequency reduced gradually per slit-lamp response, never stopped abruptly. |
| Loteprednol etabonate 0.5% ophthalmic | Adults: Per ophthalmology-directed taper | Lower, but not absent, risk of intraocular pressure elevation and cataract versus prednisolone acetate | None significant at standard ophthalmic doses | A lower-relative-risk option, particularly where a longer course of topical steroid is anticipated. |
| Difluprednate 0.05% ophthalmic emulsion | Adults: Per ophthalmology-directed taper, sometimes at reduced frequency versus prednisolone acetate for comparable effect | Higher relative potency carries a correspondingly higher risk of intraocular pressure elevation — needs closer monitoring | None significant at standard ophthalmic doses | A higher-potency option some uveitis specialists select for severe or fibrinous anterior chamber inflammation; a specialist-selected choice, not a substitution to suggest. |
Cycloplegic / Mydriatic Agents
Used alongside the corticosteroid to relieve ciliary-spasm pain and to help prevent or break posterior synechiae. Blurred near vision and photophobia from the dilated, non-accommodating pupil are expected, reversible effects to counsel on up front.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cyclopentolate 1% ophthalmic | Adults: 1 drop 2-3 times daily, per ophthalmology direction | Blurred near vision and photophobia (pupil dilation, paralyzed accommodation); rare systemic anticholinergic effects, especially in young children | Additive effects with other anticholinergic drugs | Shorter-acting than atropine; often preferred for milder disease. |
| Atropine 1% ophthalmic | Adults: 1 drop once or twice daily, per ophthalmology direction | Prolonged blurred near vision and photophobia (can last 1-2 weeks after stopping); systemic anticholinergic toxicity risk with accidental pediatric ingestion | Additive effects with other anticholinergic drugs | Longer-acting; used for more severe pain or to help break early posterior synechiae. Counsel on secure storage given pediatric toxicity risk. |
Systemic Immunosuppressive / Steroid-Sparing Therapy
Reserved for patients who respond poorly to corticosteroids, develop corticosteroid-limiting side effects, need an unacceptably high maintenance topical dose, or have a systemic inflammatory disease warranting systemic treatment. Selected, dosed, and monitored by the uveitis specialist or rheumatology — never initiated in primary care or community pharmacy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methotrexate | Adults: Individualized weekly oral or subcutaneous dosing | Hepatotoxicity, bone marrow suppression, teratogenicity | Trimethoprim-sulfamethoxazole and other antifolate drugs increase toxicity risk; NSAIDs can reduce renal clearance | Requires folic acid co-therapy and scheduled laboratory monitoring; a conventional first-choice steroid-sparing agent. |
| Azathioprine | Adults: Individualized daily oral dosing | Bone marrow suppression, hepatotoxicity, GI upset | Allopurinol markedly increases toxicity (requires dose reduction); ACE inhibitors can worsen myelosuppression | Alternative conventional steroid-sparing agent; TPMT activity is often checked before starting. |
| Mycophenolate mofetil | Adults: Individualized twice-daily oral dosing | GI upset, bone marrow suppression, teratogenicity | Reduced absorption with antacids/cholestyramine | Another conventional steroid-sparing option; contraindicated in pregnancy. |
| Cyclosporine (oral) | Adults: Individualized daily oral dosing | Nephrotoxicity, hypertension, gingival hyperplasia | Numerous — CYP3A4 substrate; levels affected by many common drugs (azole antifungals, macrolides, grapefruit juice, among others) | Requires regular renal function and blood pressure monitoring; distinct from topical ophthalmic cyclosporine used for dry eye disease. |
| Adalimumab | Adults: Specialist-directed subcutaneous injection schedule | Increased infection risk, injection-site reactions | Avoid live vaccines during therapy | Health Canada-approved specifically for non-infectious uveitis in appropriate patients; a specialist-directed biologic, not a primary-care-initiated therapy. |
| Infliximab | Adults: Specialist-directed infusion schedule | Increased infection risk, infusion reactions | Avoid live vaccines during therapy | Biologic alternative for refractory non-infectious uveitis; specialist-administered infusion. |
Antiviral Therapy for Herpetic Anterior Uveitis
Used specifically once a herpes simplex- or varicella zoster-associated cause has been identified, alongside topical anti-inflammatory therapy for the inflammation itself.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acyclovir | Adults: Individualized per the specific herpetic indication and renal function | GI upset; nephrotoxicity with inadequate hydration at high doses | Probenecid can increase acyclovir levels | Requires more frequent dosing than valacyclovir. |
| Valacyclovir | Adults: Individualized per the specific herpetic indication and renal function | GI upset; rare neurotoxicity/nephrotoxicity, particularly in renal impairment | Probenecid can increase acyclovir (active metabolite) levels | Preferred over acyclovir for its simpler dosing schedule in most patients. |
References
- Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop — American Journal of Ophthalmology (Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group). Am J Ophthalmol 2005;140(3):509-516
- Anterior Uveitis — StatPearls, StatPearls Publishing (Duplechain A, Conrady CD, Patel BC, Baker S). StatPearls [Internet], updated Aug 8, 2023
- Management and Treatment of Red Eyes in Primary Care — Canadian Primary Care Today (Bhamra J, Sylvestre-Bouchard A). Can Prim Care Today 2024;2(2):24-31
- Anterior uveitis for the comprehensive ophthalmologist — Canadian Journal of Ophthalmology (Xie JS, Ocampo V, Kaplan AJ). Can J Ophthalmol 2025;60(2):69-78
- Management of HLA-B27 Acute Anterior Uveitis — American Academy of Ophthalmology, Current Insight (Wakefield D). AAO Current Insight, Aug 7, 2009
- Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis — The Journal of Rheumatology (Berard R, Ng HY, Human A, et al., for the Canadian Rheumatology Association and the Canadian Ophthalmological Society). J Rheumatol 2023;50(3):390-399
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.